Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS (Brentuximab Vedotin) in Patients with Hodgkin Lymphoma at ISHL 2018 October 26, 2018 at 8:00 AM EDT
-Encore and Additional Analyses from Phase 3 ECHELON-1 Trial Evaluating ADCETRIS in Combination with Chemotherapy in Frontline Advanced HL- -Interim Results from Ongoing Studies of ADCETRIS plus Opdivo?(Nivolumab) in Frontline or Relapsed Hodgkin Lymphoma- -Five-Year Results from Phase 3 AETHERA Trial of ADCETRIS as HL Post-Transplant Consolidation Therapy- BOTHELL, Wash.--(BUSINESS WIRE)--- Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted multiple presentations evaluating ADCETRIS (brentuximab vedotin) across a broad range of Hodgkin lymphoma (HL) settings at the 11th International Symposium on Hodgkin Lymphoma (ISHL) taking place in Cologne, Germany, October 27-29, 2018. Data include both encore and additional analyses from the phase 3 ECHELON-1 clinical trial evaluating ADCETRIS in combination with chemotherapy in frontline Stage III or IV classical HL adult patients, which formed the basis of U.S. Food and Drug Administration (FDA) approval in this indication in March 2018. Interim results will be presented from two ongoing clinical trials evaluating ADCETRIS in combination with Opdivo (nivolumab), including in newly diagnosed older HL patients. Lastly, five-year follow-up from the phase 3 AETHERA clinical trial will be presented. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL that plays a role in tumor pathogenesis. ADCETRIS is being evaluated globally as the foundation of therapy for HL in more than 50 ongoing clinical trials. ADCETRIS and Opdivo are not approved in combination for the treatment of HL. ?After more than a decade of dedicated clinical research with ADCETRIS, we have made significant progress in improving the treatment outcomes for patients with Hodgkin lymphoma,? said Nancy Whiting, Pharm.D., Senior Vice President, Clinical Development and Global Medical Affairs at Seattle Genetics. ?At ISHL, we will present additional analyses from the ECHELON-1 trial, which demonstrated that ADCETRIS plus AVD improves upon a frontline standard of care regimen, ABVD, in advanced patients and resulted in the first change in advanced stage HL in over 40 years. In addition, three oral presentations will highlight ADCETRIS plus Opdivo combination data in frontline and relapsed/refractory HL and five-year data from the phase 3 AETHERA trial. We are pleased to share these results from our broad ADCETRIS clinical development program with the Hodgkin lymphoma community.? Multiple corporate presentations will be presented at ISHL. Abstracts will be available at www.hodgkinsymposium.org. Data from four analyses of the phase 3 ECHELON-1 clinical trial will be presented at ISHL. Importantly, an analysis from the ECHELON-1 study (Abstract #0038) will be presented in an oral presentation and poster showing PFS data per investigator that is consistent with the previously reported modified PFS data per Independent Review Facility (IRF). The ECHELON-1 abstracts include the following:
View source version on businesswire.com: https://www.businesswire.com/news/home/20181026005084/en/ Source: Seattle Genetics, Inc. Seattle Genetics, Inc. Media: Monique Greer, 425-527-4641 mgreer@seagen.com or Investors: Peggy Pinkston, 425-527-4160 ppinkston@seagen.com |